Share Price and Basic Stock Data
Last Updated: February 14, 2026, 8:25 pm
| PEG Ratio | 5.77 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bal Pharma Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹111 Cr and a share price of ₹70.1. The company’s revenue from operations for the year ending March 2025 stood at ₹303 Cr, marking a slight decline from ₹339 Cr reported for March 2024. However, the trailing twelve months (TTM) revenue was recorded at ₹295 Cr, indicating resilience amidst fluctuations. Quarterly sales figures show a positive trend, with the most recent quarter (September 2023) achieving ₹92.54 Cr, up from ₹70.39 Cr in June 2023. This reflects the company’s ability to navigate seasonal variations and enhance its market presence. Bal Pharma’s steady sales growth in recent quarters, particularly in the September 2023 quarter, demonstrates its operational agility and market demand for its products. The overall industry growth, supported by rising healthcare needs, positions Bal Pharma to capitalize on increasing pharmaceutical demands in India.
Profitability and Efficiency Metrics
Bal Pharma’s profitability metrics reveal a mixed performance over the recent quarters. The operating profit margin (OPM) for the year ending March 2025 stood at 10%, reflecting a recovery from 9% in March 2024. The latest quarterly OPM reported for September 2023 was 8.32%, a slight decline from 9.15% in June 2023. Net profit for the year ending March 2025 was reported at ₹7 Cr, consistent with the previous year, while the trailing twelve months’ net profit was ₹7 Cr. The interest coverage ratio (ICR) stood at 1.88x, indicating sufficient earnings to cover interest obligations, although this is relatively low compared to sector averages. Bal Pharma’s return on equity (ROE) was reported at 9.66%, which is slightly below the typical range for the pharmaceutical industry, suggesting room for improvement in shareholder returns. The company’s cost control measures and operational efficiency will be crucial for enhancing profitability in the competitive pharmaceutical landscape.
Balance Sheet Strength and Financial Ratios
Bal Pharma’s balance sheet reflects a debt-laden structure with total borrowings reported at ₹155 Cr against reserves of ₹62 Cr. The debt-to-equity ratio stood at 1.94x, indicating a high reliance on debt financing, which may pose risks in periods of declining revenues. The current ratio was reported at 1.07x, suggesting adequate short-term liquidity, although it is only marginally above the industry benchmark of 1.0x. The company’s book value per share, recorded at ₹48.63 for March 2025, indicates a solid asset base relative to its market price. The price-to-book value (P/BV) ratio stood at 1.71x, which is within a reasonable range for the sector. Additionally, Bal Pharma’s return on capital employed (ROCE) was reported at 18.92%, reflecting effective utilization of capital despite the high debt levels. The company’s ability to manage debt while maintaining operational efficiency will be key to sustaining its financial health and growth prospects.
Shareholding Pattern and Investor Confidence
The shareholding structure of Bal Pharma shows a stable promoter holding of 50.87%, with foreign institutional investors (FIIs) holding a marginal 0.23%. Public shareholding accounts for 48.91%, indicating a balanced distribution of ownership among stakeholders. The total number of shareholders stood at 15,774, suggesting a robust retail investor interest. Notably, promoter shareholding has witnessed a gradual decline from 51.61% in December 2022 to the current 50.87%, which could signal a potential dilution of control. However, the consistent percentage of public shareholding and the recent increase in FII stake from 0.18% in December 2022 to 0.23% in September 2025 demonstrates growing investor confidence in Bal Pharma’s long-term prospects. The stability in shareholding, combined with a consistent dividend payout ratio of 26.47% in March 2025, further reinforces investor trust in the company’s financial performance.
Outlook, Risks, and Final Insight
Looking ahead, Bal Pharma faces a mix of opportunities and challenges. The company’s strong sales growth in recent quarters positions it well for future revenue expansion, particularly in the context of India’s growing healthcare demands. However, the high debt levels and fluctuating profit margins present significant risks that could impact financial stability if not managed effectively. Additionally, the pharmaceutical industry is subject to regulatory changes and market competition, which could affect profitability. Bal Pharma must focus on improving operational efficiencies and maintaining a healthy balance sheet to mitigate these risks. Should the company successfully enhance its profit margins and reduce debt, it could unlock further value for shareholders. Conversely, failure to address these challenges may hinder growth and investor confidence. Overall, Bal Pharma’s strategic initiatives in addressing financial and operational challenges will be crucial in determining its future trajectory in the pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 137/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,402 Cr. | 312 | 479/192 | 71.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 338 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,956.81 Cr | 1,098.00 | 54.79 | 201.74 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 75.31 | 76.62 | 82.45 | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 |
| Expenses | 69.53 | 70.47 | 74.29 | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 | 68.29 |
| Operating Profit | 5.78 | 6.15 | 8.16 | 6.44 | 7.70 | 7.79 | 9.60 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 |
| OPM % | 7.67% | 8.03% | 9.90% | 9.15% | 8.32% | 9.54% | 10.14% | 8.70% | 10.44% | 10.59% | 9.33% | 9.20% | 7.74% |
| Other Income | 0.05 | 0.46 | 0.19 | 0.16 | 0.14 | 0.10 | 2.45 | 0.82 | -0.20 | 0.51 | 1.08 | 0.72 | 1.12 |
| Interest | 2.86 | 3.11 | 3.85 | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 |
| Depreciation | 2.37 | 2.45 | 2.09 | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 |
| Profit before tax | 0.60 | 1.05 | 2.41 | 0.43 | 1.60 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 |
| Tax % | 78.33% | 43.81% | 32.78% | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.00% | 0.00% |
| Net Profit | 0.12 | 0.59 | 1.62 | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 |
| EPS in Rs | 0.07 | 0.36 | 1.02 | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.30 | 3.41 | 0.13 | 0.45 |
Last Updated: January 2, 2026, 8:31 am
Below is a detailed analysis of the quarterly data for Bal Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 74.02 Cr.. The value appears strong and on an upward trend. It has increased from 65.87 Cr. (Jun 2025) to 74.02 Cr., marking an increase of 8.15 Cr..
- For Expenses, as of Sep 2025, the value is 68.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 59.81 Cr. (Jun 2025) to 68.29 Cr., marking an increase of 8.48 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.73 Cr.. The value appears to be declining and may need further review. It has decreased from 6.06 Cr. (Jun 2025) to 5.73 Cr., marking a decrease of 0.33 Cr..
- For OPM %, as of Sep 2025, the value is 7.74%. The value appears to be declining and may need further review. It has decreased from 9.20% (Jun 2025) to 7.74%, marking a decrease of 1.46%.
- For Other Income, as of Sep 2025, the value is 1.12 Cr.. The value appears strong and on an upward trend. It has increased from 0.72 Cr. (Jun 2025) to 1.12 Cr., marking an increase of 0.40 Cr..
- For Interest, as of Sep 2025, the value is 3.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.05 Cr. (Jun 2025) to 3.86 Cr., marking a decrease of 0.19 Cr..
- For Depreciation, as of Sep 2025, the value is 2.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.52 Cr. (Jun 2025) to 2.27 Cr., marking a decrease of 0.25 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Jun 2025) to 0.72 Cr., marking an increase of 0.51 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Jun 2025) to 0.72 Cr., marking an increase of 0.51 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.45. The value appears strong and on an upward trend. It has increased from 0.13 (Jun 2025) to 0.45, marking an increase of 0.32.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 179 | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 295 |
| Expenses | 161 | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 268 |
| Operating Profit | 18 | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 27 |
| OPM % | 10% | 9% | 7% | 6% | 8% | 8% | 3% | 10% | 9% | 8% | 9% | 10% | 9% |
| Other Income | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 3 |
| Interest | 7 | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 |
| Depreciation | 5 | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 7 | 5 | 3 | 3 | 3 | -0 | -14 | 4 | 9 | 5 | 9 | 5 | 4 |
| Tax % | 23% | 25% | 90% | 114% | 87% | -1,175% | -5% | -15% | 38% | 45% | 18% | -41% | |
| Net Profit | 5 | 4 | 1 | -0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 7 |
| EPS in Rs | 4.56 | 2.82 | 1.10 | 1.24 | 1.96 | 2.67 | -8.62 | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 | 4.29 |
| Dividend Payout % | 22% | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -20.00% | -75.00% | -100.00% | -750.00% | 138.46% | 20.00% | -50.00% | 133.33% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -25.00% | -650.00% | 888.46% | -118.46% | -70.00% | 183.33% | -133.33% |
Bal Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 3% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 21% |
| 3 Years: | 13% |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | -3% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 12:20 am
Balance Sheet
Last Updated: December 4, 2025, 1:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 39 | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 62 |
| Borrowings | 51 | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 155 |
| Other Liabilities | 54 | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 116 |
| Total Liabilities | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 349 |
| Fixed Assets | 55 | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 92 |
| CWIP | 0 | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 0 |
| Other Assets | 99 | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 253 |
| Total Assets | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 349 |
Below is a detailed analysis of the balance sheet data for Bal Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 62.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 155.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 150.00 Cr. (Mar 2025) to 155.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 116.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Mar 2025) to 116.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 349.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 336.00 Cr. (Mar 2025) to 349.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 87.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 5.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 253.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2025) to 253.00 Cr., marking an increase of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 349.00 Cr.. The value appears strong and on an upward trend. It has increased from 336.00 Cr. (Mar 2025) to 349.00 Cr., marking an increase of 13.00 Cr..
However, the Borrowings (155.00 Cr.) are higher than the Reserves (62.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -33.00 | -32.00 | -74.00 | -78.00 | -93.00 | -106.00 | -113.00 | -85.00 | -80.00 | -106.00 | -109.00 | -120.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 |
| Inventory Days | 122 | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 |
| Days Payable | 129 | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 |
| Cash Conversion Cycle | 86 | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 |
| Working Capital Days | 11 | 14 | 50 | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 |
| ROCE % | 11% | 7% | 8% | 8% | 7% | -0% | 10% | 12% | 10% | 12% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.54 | 4.94 | 1.67 | 3.79 | 3.34 |
| Diluted EPS (Rs.) | 4.54 | 4.96 | 1.68 | 3.79 | 3.34 |
| Cash EPS (Rs.) | 10.68 | 11.08 | 7.49 | 9.95 | 9.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Revenue From Operations / Share (Rs.) | 190.37 | 214.64 | 193.89 | 189.72 | 169.02 |
| PBDIT / Share (Rs.) | 19.95 | 21.75 | 16.61 | 19.31 | 17.27 |
| PBIT / Share (Rs.) | 13.81 | 15.38 | 10.79 | 13.21 | 10.85 |
| PBT / Share (Rs.) | 3.23 | 5.72 | 3.03 | 6.20 | 2.77 |
| Net Profit / Share (Rs.) | 4.54 | 4.71 | 1.67 | 3.85 | 3.18 |
| NP After MI And SOA / Share (Rs.) | 4.53 | 4.68 | 1.64 | 3.79 | 3.20 |
| PBDIT Margin (%) | 10.47 | 10.13 | 8.56 | 10.18 | 10.21 |
| PBIT Margin (%) | 7.25 | 7.16 | 5.56 | 6.96 | 6.41 |
| PBT Margin (%) | 1.69 | 2.66 | 1.56 | 3.26 | 1.63 |
| Net Profit Margin (%) | 2.38 | 2.19 | 0.86 | 2.02 | 1.88 |
| NP After MI And SOA Margin (%) | 2.38 | 2.17 | 0.84 | 1.99 | 1.89 |
| Return on Networth / Equity (%) | 9.32 | 10.66 | 4.03 | 9.57 | 8.85 |
| Return on Capital Employeed (%) | 18.92 | 20.86 | 16.30 | 20.64 | 18.36 |
| Return On Assets (%) | 2.14 | 2.31 | 0.82 | 2.15 | 1.97 |
| Long Term Debt / Equity (X) | 0.40 | 0.52 | 0.47 | 0.46 | 0.44 |
| Total Debt / Equity (X) | 1.94 | 2.01 | 2.05 | 1.67 | 1.95 |
| Asset Turnover Ratio (%) | 0.92 | 1.07 | 1.06 | 1.12 | 0.99 |
| Current Ratio (X) | 1.07 | 1.15 | 1.09 | 1.11 | 1.08 |
| Quick Ratio (X) | 0.60 | 0.72 | 0.62 | 0.66 | 0.68 |
| Inventory Turnover Ratio (X) | 3.18 | 1.95 | 2.08 | 2.43 | 2.12 |
| Dividend Payout Ratio (NP) (%) | 26.47 | 21.22 | 60.55 | 26.41 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 11.24 | 8.98 | 13.30 | 10.11 | 0.00 |
| Earning Retention Ratio (%) | 73.53 | 78.78 | 39.45 | 73.59 | 0.00 |
| Cash Earning Retention Ratio (%) | 88.76 | 91.02 | 86.70 | 89.89 | 0.00 |
| Interest Coverage Ratio (X) | 1.88 | 2.25 | 2.14 | 2.75 | 2.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.43 | 1.49 | 1.21 | 1.55 | 1.39 |
| Enterprise Value (Cr.) | 274.72 | 270.49 | 228.31 | 252.09 | 180.34 |
| EV / Net Operating Revenue (X) | 0.90 | 0.79 | 0.75 | 0.89 | 0.71 |
| EV / EBITDA (X) | 8.65 | 7.87 | 8.76 | 8.81 | 7.05 |
| MarketCap / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| Retention Ratios (%) | 73.52 | 78.77 | 39.44 | 73.58 | 0.00 |
| Price / BV (X) | 1.71 | 2.08 | 1.65 | 2.73 | 1.49 |
| Price / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| EarningsYield | 0.05 | 0.05 | 0.02 | 0.03 | 0.05 |
After reviewing the key financial ratios for Bal Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.94 (Mar 24) to 4.54, marking a decrease of 0.40.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.96 (Mar 24) to 4.54, marking a decrease of 0.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.68. This value is within the healthy range. It has decreased from 11.08 (Mar 24) to 10.68, marking a decrease of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 190.37. It has decreased from 214.64 (Mar 24) to 190.37, marking a decrease of 24.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 19.95. This value is within the healthy range. It has decreased from 21.75 (Mar 24) to 19.95, marking a decrease of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.81. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.81, marking a decrease of 1.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.23. This value is within the healthy range. It has decreased from 5.72 (Mar 24) to 3.23, marking a decrease of 2.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.54. This value is within the healthy range. It has decreased from 4.71 (Mar 24) to 4.54, marking a decrease of 0.17.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.53. This value is within the healthy range. It has decreased from 4.68 (Mar 24) to 4.53, marking a decrease of 0.15.
- For PBDIT Margin (%), as of Mar 25, the value is 10.47. This value is within the healthy range. It has increased from 10.13 (Mar 24) to 10.47, marking an increase of 0.34.
- For PBIT Margin (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 7.16 (Mar 24) to 7.25, marking an increase of 0.09.
- For PBT Margin (%), as of Mar 25, the value is 1.69. This value is below the healthy minimum of 10. It has decreased from 2.66 (Mar 24) to 1.69, marking a decrease of 0.97.
- For Net Profit Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 5. It has increased from 2.19 (Mar 24) to 2.38, marking an increase of 0.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 8. It has increased from 2.17 (Mar 24) to 2.38, marking an increase of 0.21.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.32. This value is below the healthy minimum of 15. It has decreased from 10.66 (Mar 24) to 9.32, marking a decrease of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.92. This value is within the healthy range. It has decreased from 20.86 (Mar 24) to 18.92, marking a decrease of 1.94.
- For Return On Assets (%), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 5. It has decreased from 2.31 (Mar 24) to 2.14, marking a decrease of 0.17.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.40, marking a decrease of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.94. This value exceeds the healthy maximum of 1. It has decreased from 2.01 (Mar 24) to 1.94, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.92. It has decreased from 1.07 (Mar 24) to 0.92, marking a decrease of 0.15.
- For Current Ratio (X), as of Mar 25, the value is 1.07. This value is below the healthy minimum of 1.5. It has decreased from 1.15 (Mar 24) to 1.07, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.60, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.18. This value is below the healthy minimum of 4. It has increased from 1.95 (Mar 24) to 3.18, marking an increase of 1.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.47. This value is within the healthy range. It has increased from 21.22 (Mar 24) to 26.47, marking an increase of 5.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.24. This value is below the healthy minimum of 20. It has increased from 8.98 (Mar 24) to 11.24, marking an increase of 2.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.53. This value exceeds the healthy maximum of 70. It has decreased from 78.78 (Mar 24) to 73.53, marking a decrease of 5.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.76. This value exceeds the healthy maximum of 70. It has decreased from 91.02 (Mar 24) to 88.76, marking a decrease of 2.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 3. It has decreased from 2.25 (Mar 24) to 1.88, marking a decrease of 0.37.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 3. It has decreased from 1.49 (Mar 24) to 1.43, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 274.72. It has increased from 270.49 (Mar 24) to 274.72, marking an increase of 4.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.79 (Mar 24) to 0.90, marking an increase of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 8.65. This value is within the healthy range. It has increased from 7.87 (Mar 24) to 8.65, marking an increase of 0.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For Retention Ratios (%), as of Mar 25, the value is 73.52. This value exceeds the healthy maximum of 70. It has decreased from 78.77 (Mar 24) to 73.52, marking a decrease of 5.25.
- For Price / BV (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.71, marking a decrease of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bal Pharma Ltd:
- Net Profit Margin: 2.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.92% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.6
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.8 (Industry average Stock P/E: 54.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.94
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | # 21 & 22, Bengaluru Karnataka 560099 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Ravindrakumar Kothari | Non Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Independent Director |
FAQ
What is the intrinsic value of Bal Pharma Ltd?
Bal Pharma Ltd's intrinsic value (as of 15 February 2026) is ₹58.64 which is 22.02% lower the current market price of ₹75.20, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹120 Cr. market cap, FY2025-2026 high/low of ₹129/64.0, reserves of ₹62 Cr, and liabilities of ₹349 Cr.
What is the Market Cap of Bal Pharma Ltd?
The Market Cap of Bal Pharma Ltd is 120 Cr..
What is the current Stock Price of Bal Pharma Ltd as on 15 February 2026?
The current stock price of Bal Pharma Ltd as on 15 February 2026 is ₹75.2.
What is the High / Low of Bal Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bal Pharma Ltd stocks is ₹129/64.0.
What is the Stock P/E of Bal Pharma Ltd?
The Stock P/E of Bal Pharma Ltd is 14.8.
What is the Book Value of Bal Pharma Ltd?
The Book Value of Bal Pharma Ltd is 49.2.
What is the Dividend Yield of Bal Pharma Ltd?
The Dividend Yield of Bal Pharma Ltd is 1.60 %.
What is the ROCE of Bal Pharma Ltd?
The ROCE of Bal Pharma Ltd is 10.1 %.
What is the ROE of Bal Pharma Ltd?
The ROE of Bal Pharma Ltd is 9.66 %.
What is the Face Value of Bal Pharma Ltd?
The Face Value of Bal Pharma Ltd is 10.0.